Výsledky vyhledávání - "V Quagliariello"

Akademický článek

Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity

Autor: V. Quagliariello, M. L. Canale, I. Bisceglia, M. Iovine, A. Paccone, C. Maurea, M. Scherillo, A. Merola, V. Giordano, G. Palma, A. Luciano, F. Bruzzese, F. Zito Marino, M. Montella, R. Franco, M. Berretta, D. Gabrielli, G. Gallucci, N. Maurea

Publikováno v: Frontiers in Cardiovascular Medicine, Vol 11 (2024)

BackgroundAnthracycline-mediated adverse cardiovascular events are among the leading causes of morbidity and mortality in patients with cancer. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) exert multiple cardiometabolic benefits in patients wit

Externí odkaz: https://doaj.org/article/4ac4e155429d46e6862977792ad67451

Zobrazit plný text záznamu

Akademický článek

Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects

Autor: S. Cortellino, V. Quagliariello, G. Delfanti, O. Blaževitš, C. Chiodoni, N. Maurea, A. Di Mauro, F. Tatangelo, F. Pisati, A. Shmahala, S. Lazzeri, V. Spagnolo, E. Visco, C. Tripodo, G. Casorati, P. Dellabona, V. D. Longo

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)

Abstract Immune checkpoint inhibitors cause side effects ranging from autoimmune endocrine disorders to severe cardiotoxicity. Periodic Fasting mimicking diet (FMD) cycles are emerging as promising enhancers of a wide range of cancer therapies includ

Externí odkaz: https://doaj.org/article/84e0c2a914ff43729633608ba3f0023b

Zobrazit plný text záznamu

Akademický článek

Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology

Autor: V. Quagliariello, M. Passariello, I. Bisceglia, A. Paccone, A. Inno, C. Maurea, R. Rapuano Lembo, L. Manna, M. Iovine, M. L. Canale, M. Scherillo, P. A. Ascierto, D. Gabrielli, C. De Lorenzo, N. Maurea

Publikováno v: Frontiers in Cardiovascular Medicine, Vol 11 (2024)

BackgroundImmune checkpoint blockade in monotherapy or combinatorial regimens with chemotherapy or radiotherapy have become an integral part of oncology in recent years. Monoclonal antibodies against CTLA-4 or PD-1 or PDL-1 are the most studied ICIs

Externí odkaz: https://doaj.org/article/c7cf13326e4540e69be594a83633eb43

Zobrazit plný text záznamu

Akademický článek

Improved Survival and Quality of Life Through an Integrative, Multidisciplinary Oncological Approach: Pathophysiological Analysis of Four Clinical Cancer Cases and Review of the Literature

Autor: M. Berretta, A. Morra, R. Taibi, F. Monari, N. Maurea, M. Ippolito, U. Tirelli, F. Fiorica, L. Montella, G. Facchini, V. Quagliariello, M. Montopoli

Publikováno v: Frontiers in Pharmacology, Vol 13 (2022)

Objectives: According to the National Cancer Institute, the integrative medicine (IM) approach to medical care combines standard medicine with complementary and alternative medicine practices that have proved safe and effective.Methods: We describe t

Externí odkaz: https://doaj.org/article/9470c019fe3d46c69106038c9b377120

Zobrazit plný text záznamu

Berberine associated to SGLT2i Dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to Trastuzumab through reduction of AGEs and IL-6 and induction of pAMPK

Autor: N Maurea, S Buccolo, M Iovine, C Maurea, A Paccone, V Quagliariello

Publikováno v: European Heart Journal. 43

Background Trastuzumab has improved the prognosis in patients with HER2-positive breast cancer, but it can induce left ventricular dysfunction with reduced ejection fraction or HF during treatment. Dapagliflozin is a SGLT2i with cardio-renal benefits

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f8d3aff6086c137278ebb4167912ddb4
https://doi.org/10.1093/eurheartj/ehac544.2729

Zobrazit plný text záznamu

Sacubitril-valsartan activates pAMPK and reduces NLRP3, MyD88, cytokines/growth factors and DAMPs in doxorubicin-treated mice improving longitudinal strain and ejection fraction

Autor: N Maurea, S Buccolo, M Iovine, A Paccone, A Luciano, A Barbieri, G Palma, C Maurea, V Quagliariello

Publikováno v: European Heart Journal. 43

Background Doxorubicin-mediated adverse cardiovascular events are among the leading causes of morbidity and mortality in breast cancer patients. Sacubitril-valsartan (LCZ 696) is a combination drug, made up of neprilysin inhibitor sacubitril and angi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fc5da3ab5a979b1679795c78fb2e3337
https://doi.org/10.1093/eurheartj/ehac544.2727

Zobrazit plný text záznamu

Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue

Autor: N Maurea, C De Lorenzo, M Passariello, M Iovine, S Buccolo, A Di Mauro, C Cipullo, A Paccone, F Maurea, A Caronna, V Quagliariello

Publikováno v: European Heart Journal. 43

Background Several strategies based on immune checkpoint inhibitors (ICIs) have been developed or are under investigation for cancer therapy, opening to advantages in cancer outcomes. However, several ICIs-induced side effects emerged in these patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3d36c08db71e8d41e391330a7a7e424d
https://doi.org/10.1093/eurheartj/ehac544.2728

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P383 DAPAGLIFLOZIN REDUCES SYSTEMIC PCSK9 LEVELS IN PRECLINICAL MODELS OF SHORT–TERM DOXORUBICIN CARDIOTOXICITY THROUGH NLRP3 INFLAMMASOME/IL–1Β: A FIRST EVIDENCE OF SGLT–2/PCSK9 CROSS–TALK IN CARDIONCOLOGY

Autor: V Quagliariello, G Palma, A Luciano, F Bruzzese, A Paccone, M Iovine, N Maurea

Publikováno v: European Heart Journal Supplements. 25:D195-D195

Background Anthracyclines are an effective and widely used chemotherapy agent in the treatment of multiple solid organ tumors and hematologic malignancies. The use of anthracyclines as a standard cancer therapy is limited by the potential for the dev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ef962acca4422c49285b11c7aad97103
https://doi.org/10.1093/eurheartjsupp/suad111.455

Zobrazit plný text záznamu

P470 BERBERINE ASSOCIATED TO DAPAGLIFLOZIN EXERTS SYNERGISTIC CARDIOPROTECTIVE EFFECTS IN CARDIAC CELLS EXPOSED TO THE HER2–BLOKING AGENT TRASTUZUMAB THROUGH PAMPK ACTIVATION AND REDUCTION IN INTERLEUKIN–6 LEVELS

Autor: V Quagliariello, M Scherillo, F Maurea, M Iovine, A Paccone, N Maurea

Publikováno v: European Heart Journal Supplements. 25:D227-D227

Background Trastuzumab has improved the prognosis in patients with HER2–positive breast cancer, but it can induce left ventricular dysfunction with reduced ejection fraction or HF during treatment. Dapagliflozin is a SGLT2i with cardio–renal bene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e73511e157f494d7775827206e2dc409
https://doi.org/10.1093/eurheartjsupp/suad111.532

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání